and nonalcoholic fatty liver disease (NAFLD). Eight broad categories of risks are summarized. efit or risk.*
ATIONS*
Thiazolidinedione (TZD)
EFITS Mild Moderate Moderate SKS
Neutral Neutral
Mild Moderate Mild / Moderate
Contraindicated in class 3,4 CHF
Moderate Moderate Neutral
Neutral
Neutral Neutral Neutral
Neutral
Neutral Neutral Neutral
Neutral Moderate Neutral Neutral Neutral Moderate Neutral Neutral
Moderate to Severe
Neutral Moderate Neutral
Neutral unless with TZD
Moderate Neutral
Mild to Neutral Neutral Moderate Unknown Neutral Neutral
Benefit Neutral Neutral
© AACE December 2009 Update. May not be reproduced in any form without express written permission from AACE
Disclaimer This Guideline attempts to define principles of practice that should produce high-quality patient care. It focuses on the needs of primary care practice, but also is applicable to providers at all levels. This Guideline should not be considered exclusive of other methods of care reasonably directed at obtaining the same results. The ultimate judgment concerning the propriety of any course of conduct must be made by the clinician aſter consideration of each individual patient situation. Neither IGC, the medical associations, nor the authors endorse any product or service associated with the distributor of this clinical reference tool.
5740 Executive Drive Suite 220 Baltimore, MD 21228 TEL: 410-869-3332 • FAX: 410-744-2150 For additional copies: orders@GuidelineCentral.com Copyright © 2010 All rights reserved
Mild Mild Neutral Moderate Neutral Neutral
Moderate to Marked
Moderate to Marked
Neutral
Moderate to Marked
Mild Neutral Colesevelam
glucosidase inhibitor (AGI)
Alpha- Insulin Pramlintide
